Agreement to Combine Merck’s Investigational Anti-PD-1 and Key Pfizer Oncology Assets.) Pfizer Inc. (NYSE:PFE) announced that it has agreed with Merck & Co., Inc., known as MSD outside the United States and Canada (“Merck”), through two Merck subsidiaries, to explore the therapeutic potential of Merck’s investigational anti-PD-1 therapy, MK-3475, in combination with two Pfizer oncology …
Continue reading “Pfizer And Merck To Collaborate On Innovative Anti-Cancer Combination Studies”